$4.590
+0.020 (+0.44%)Al cierre
Noticias de TLRY
Eventos de TLRY
Tilray Expands Global Cannabis Cultivation Capacity to 275 Metric Tons
Tilray announced a major expansion of its global cannabis cultivation capacity to meet accelerating international medical cannabis demand. Across its worldwide operations, Tilray has increased annual cultivation capacity to approximately 275 metric tons, up from 210 metric tons, driven by expanded output at its Quebec facility in Canada and its EU-GMP-certified facility in Portugal. The Quebec facility is also on track to achieve EU-GMP certification within the next 12 months.
Tilray Reports Q4 Revenue of $281.7M
Reports Q4 revenue $281.7M, consensus $246.3M. Reports Q4 beverage net revenue was $105.6M. Reports Q4 cannabis net revenue increased 5% to $71.5M. "Fiscal 2026 marks an important milestone in Tilray's evolution. We didn't just deliver record revenue, record gross profit and record adjusted EBITDA, we demonstrated the strength of the diversified global platform we've been building for the last five years," said CEO Irwin Simon.
Sees FY27 Adjusted EBITDA of $68M-$75M
Sees FY27 adjusted EBITDA of $68M-$75M, representing double-digit growth compared to FY26.
Starfighters Space Borrow Rate Increases to 116.23%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 116.23% +6.71, SpendSmart Networks Inc (SSPC) 58.19% +6.31, Leverage Shares 2X Long SPCX Daily ETF (SPCH) 50.00% +5.10, Critical Metals Corp (CRML) 67.53% +4.11, Advanced Semiconductor (ASX) 14.23% +3.43, Ambarella (AMBA) 3.65% +3.37, Tilray (TLRY) 9.36% +3.00, Angion Biomedica Corp (ELTX) 113.87% +1.97, Microvision (MVIS) 63.24% +1.41, and Defiance Daily Target 2x Long OKLO ETF (OKLL) 14.35% +1.33.
Tilray Acquires HelloMD to Expand Medical Cannabis Business
Tilray Brands announced the acquisition of HelloMD, a digital healthcare and patient engagement platform that expands Tilray's direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy. Tilray was the successful bidder in HelloMD's formal sale process and plans to acquire HelloMD's Canadian medical cannabis assets following formal Court approval on June 29. Financial terms of the transaction were not disclosed.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.